Table of Contents
The Clinitech Laboratory IPO is an exciting opportunity to invest in Clinitech Laboratory Limited, a company founded in March 2010, providing diagnostic and health testing services through a chain of 8 diagnostic centers in and around Thane and Navi Mumbai. With promoters boasting over 30 years of experience in the diagnostics industry, Clinitech Laboratory conducts more than 3 lakh tests annually in their NABL accredited laboratories equipped with modern technology and high-end equipment. The company offers a comprehensive range of over 150 tests, including biochemical, immunological, hematology, molecular biology, serological, microbiological, and histopathological examinations.
Clinitech Laboratory IPO Details
IPO Open Date | IPO Closed Date | Allotment Date |
25th July 2024 | 29th July 2024 | 30th July 2024 |
| Refunds Date | Credit of Shares | IPO Listing Date |
| 31st July 2024 | 31st July 2024 | 01st Aug 2024 |
| IPO Issue Size | IPO Issue Price | Market Lot | Total Shares |
| ₹5.78 Cr | ₹ 96.00 | 1200 Shares | 602,400 |
| Application | Lots | Shares | Amount |
| Retail(Min) | 1 | 1200 | ₹ 1,15,200 |
| Retail(Max) | 1 | 1200 | ₹ 1,15,200 |
| Small-HNI (Min) | 2 | 2400 | ₹ 2,30,400 |
| Small-HNI (Max) | 8 | 9600 | ₹ 9,21,600 |
| Big-HNI (Min) | 9 | 10800 | ₹ 10,36,800 |
| RII (Retail) | NII | QIB |
| 50.00% | 50.00% | – |
| Pre-Promoter | Post Promoter | Listing IN |
| 83.63% | 61.56% | BSE SME |
| No | Objectives |
| 1 | Expansion of Diagnostic Centres |
| 2 | General corporate purposes |
| LEAD | REGISTRAR |
| FIRST OVERSEAS CAPITAL LIMITED | BIGSHARE SERVICES PRIVATE LIMITED |
| Telephone | |
| ipo@clinitechlab.com | +91 22 27792281 / +91 |
Clinitech Laboratory IPO Allotment Chances Calculator
| Allotment Status | Allotment Chances |
| Click Here | Click Here |
Financial of Clinitech Laboratory IPO
| Amounts in Lakhs ₹ | |||
| Particulars | FY-2024 | FY-2023 | FY-2022 |
| Assets | 561 | 603 | 369 |
| Revenue | 644 | 636 | 646 |
| Expense | 542 | 500 | 532 |
| Net Worth | 355 | 238 | 185 |
| Borrowing | 86 | 103 | 89 |
| EBITDA(%) | 15.87 | 21.53 | 17.64 |
| Reserves | 187 | 88 | 35 |
| PAT | 37 | 61 | 51 |
| EPS | 2.37 | 4.09 | 3.42 |
| Debt/Equity | 0.24 | 0.41 | 0.40 |
| Established | Website | Industry |
| 2010 | ctllab.in | Healthcare |
Statement of Assets and Liabilities
Statement of Profit and Loss
Statement of Cash Flows
A Game-Changer You Definitely Didn't Know About: IPO Allotment Calculator by SwiftTopics.com
Introducing a groundbreaking tool for IPO enthusiasts – India’s first Clinitech Laboratory IPO allotment calculator, brought to you by SwiftTopics.com. This innovative calculator empowers users with a swift and secure way to assess the probability of IPO allotment without the need for any login credentials. Seamlessly designed, it provides accurate insights into the allotment chances for upcoming IPOs, including the highly anticipated offering from Clinitech Laboratory IPO.
SwiftTopics.com‘s IPO allotment calculator stands out for its user-friendly interface, offering a quick and hassle-free experience. Investors and IPO enthusiasts can simply input the relevant details, and the calculator generates a precise probability of IPO allotment, aiding in informed decision-making. Whether you’re a seasoned investor or a newcomer to the IPO landscape, this tool ensures accessibility and efficiency.
To explore this game-changing IPO allotment calculator and elevate your IPO investment experience, click here:
Unlock the potential for accurate and timely information, making your IPO journey with Clinitech Laboratory IPO and other offerings a more informed and confident endeavor.
1. Clinitech Laboratory IPO key dates & Issue Details
The Clinitech Laboratory IPO is set to open on 25th July 2024 and close on 29th July 2024. Investors can subscribe to this SME IPO at a fixed price of ₹96.00 per share. The IPO is being listed on the BSE SME, and it aims to raise ₹5.78 crore through a fresh issue. With a face value of ₹10 per equity share, the IPO has a retail quota of 50% of the net issue. Currently, the promoter holding stands at 83.63%, which will reduce to 61.56% post-IPO.
Clinitech Laboratory SME IPO Important Dates
Mark your calendars for the key dates of the Clinitech Laboratory IPO. The basis of allotment will be announced on 30th July 2024. Refunds will be initiated on 31st July 2024, and shares will be credited to demat accounts on the same day. Finally, the Clinitech Laboratory IPO will be listed on 1st August 2024. These dates are tentative and will be updated as they are officially announced.
Clinitech Laboratory SME IPO Lots
For those interested in the Clinitech Laboratory IPO, the issue price is set at ₹96.00 per share with a market lot of 1200 shares. The amount for one lot is ₹115,200. High Net Worth Individuals (HNIs) must subscribe to a minimum of 2400 shares, equating to two lots and an investment of ₹230,400.
Ensure to keep an eye on these critical dates and details to make the most of the Clinitech Laboratory IPO opportunity.
2. Clinitech Laboratory IPO Allotment Status
Dive into the excitement surrounding the Clinitech Laboratory IPO allotment status with ease! Satisfy your curiosity by quickly checking the IPO allotment status through a streamlined process designed for your convenience. Navigate effortlessly to the IPO allotment status check and ensure a hassle-free experience as you eagerly await the results.
Stay ahead of the curve by clicking on the provided links below to swiftly access the information you’ve been waiting for. Don’t miss out on the latest updates – verify your IPO allotment status effortlessly and stay well-informed about your Clinitech Laboratory IPO investment.
Verify Your IPO Allotment Status
Stay connected with the latest developments and secure your spot in the Clinitech Laboratory IPO journey.
3. Introduction to Clinitech Laboratory Limited
Clinitech Laboratory IPO is set to make waves in the diagnostic and healthcare services industry. Our business operates through a chain of 8 diagnostic centers located in Thane and Navi Mumbai. With over 30 years of experience, our promoters have built a reputable name in the diagnostic business. Annually, we conduct more than 3 lakh tests in our NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited labs, equipped with modern technology and high-end equipment. We offer a wide range of over 150 tests including biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology tests.
Competitive Strengths
1. NABL Accreditation: Our NABL accreditation as per ISO 15189:2012 for our Airoli, Navi Mumbai facility underscores our commitment to quality and instills confidence in our customers.
2. Chain of Diagnostic Centers: With 8 centers in Thane, Raigad, and Navi Mumbai, Clinitech Laboratory IPO leverages 30+ years of experience, earning trust and recognition as a leading pathology lab in the region.
3. Experienced Promoters and Management Team: Led by founders Jagdish Umakant Nayak and Jyoti Jagdish Nayak, our management team boasts significant industry expertise and a successful track record. Their leadership has been pivotal in our growth and reputation.
4. Strong and Long-standing Customer Relationships: Our three-decade-long experience has fostered strong customer relationships, resulting in repeat business and high customer retention. We aim to be the “first choice service provider” for all our customers.
Strategies for Growth
1. Leveraging Existing Products/Services Portfolio: Clinitech Laboratory IPO continues to meet healthcare needs with a range of tailored products, ensuring customer satisfaction and repeat orders.
2. Utilizing Infrastructure: Our advanced diagnostic technologies, including sensors, IoT devices, and predictive analytics, enhance our monitoring and diagnosis capabilities, allowing us to serve our customers efficiently.
3. Collaboration and Continuous Training: We promote collaboration and continuous training among our team to stay updated with industry practices, ensuring continuous improvement in our services.
4. Inorganic Growth: Clinitech Laboratory IPO plans to expand through acquisitions and joint ventures, targeting new geographies and verticals to grow our business and enhance our product/service portfolio.
Our Products and Services
Clinitech Laboratory IPO specializes in clinical pathology, providing crucial diagnostic information through various tests and techniques. Our biochemistry, serology, microbiology, hematology, molecular biology, immunology, and histopathology tests play a vital role in disease diagnosis and patient care.
Operational Process
From patient registration to result delivery, our meticulous process ensures accuracy and reliability. Samples are carefully collected, labelled, transported, and analyzed using advanced techniques. Our team interprets the results, generates detailed reports, and communicates findings to healthcare providers, ensuring comprehensive patient care.
For more information on the Clinitech Laboratory IPO, its business model, and growth strategies, stay tuned to our blog.
4. Financial Details of Clinitech Laboratory Limited
Clinitech Laboratory Limited Financial Information (Restated)
Clinitech Laboratory IPO has showcased notable financial trends over the past few years. For the financial year ending March 31, 2024, the company’s revenue saw a slight increase of 1.19% compared to the previous year, reaching ₹643.92 lakhs. However, the profit after tax (PAT) experienced a significant decline of 39.46%, dropping to ₹37.12 lakhs. Here’s a detailed breakdown of the financial metrics for the periods ending March 31:
– Assets: ₹560.79 lakhs in 2024, down from ₹603.33 lakhs in 2023.
– Revenue: ₹643.92 lakhs in 2024, slightly up from ₹636.34 lakhs in 2023.
– Profit After Tax: ₹37.12 lakhs in 2024, down from ₹61.31 lakhs in 2023.
– Net Worth: ₹354.80 lakhs in 2024, up from ₹238.08 lakhs in 2023.
– Reserves and Surplus: ₹186.80 lakhs in 2024, significantly higher than ₹88.08 lakhs in 2023.
– Total Borrowing: ₹86.31 lakhs in 2024, down from ₹102.91 lakhs in 2023.
Clinitech Laboratory IPO Valuations & Margins
The valuation metrics for Clinitech Laboratory IPO reveal significant insights into the company’s performance over the past three fiscal years. Here are the key figures:
– EPS (Earnings Per Share): ₹2.37 in FY 2024, ₹4.09 in FY 2023, and ₹3.42 in FY 2022.
– PE Ratio: 40.51 in FY 2024.
– RONW (Return on Net Worth): 10.46% in FY 2024, 25.75% in FY 2023, and 27.74% in FY 2022.
– NAV (Net Asset Value): ₹21.12 in FY 2024, ₹15.87 in FY 2023, and ₹12.32 in FY 2022.
– ROCE (Return on Capital Employed): 12.0% in FY 2024, 25.0% in FY 2023, and 24.0% in FY 2022.
– EBITDA Margin: 15.87% in FY 2024, 21.53% in FY 2023, and 17.64% in FY 2022.
– Debt/Equity Ratio: 0.24 in FY 2024, 0.41 in FY 2023, and 0.40 in FY 2022.
Financial Performance Highlights
Examining the financial performance of Clinitech Laboratory IPO for the first half of the fiscal year 2024 and previous fiscal years highlights the company’s trajectory. As of September 30, 2023:
– Total Revenue: ₹308.12 lakhs, with the fiscal year 2023 closing at ₹636.34 lakhs, and previous years at ₹645.7 lakhs in 2022 and ₹459.63 lakhs in 2021.
– EBITDA: ₹29.56 lakhs for the period ending September 30, 2023, compared to ₹136.69 lakhs in FY 2023, ₹113.92 lakhs in FY 2022, and ₹86.64 lakhs in FY 2021.
– EBITDA Margin: 9.59% for the period ending September 30, 2023, down from 21.48% in FY 2023.
– PAT: ₹6.78 lakhs for the period ending September 30, 2023, compared to ₹61.31 lakhs in FY 2023.
– PAT Margin: 2.20% for the period ending September 30, 2023, down from 9.63% in FY 2023.
– Net Debt: ₹46.43 lakhs for the period ending September 30, 2023, compared to ₹24.56 lakhs in FY 2023.
– Total Equity: ₹150.00 lakhs for the period ending September 30, 2023.
– Net Worth: ₹244.86 lakhs for the period ending September 30, 2023.
– RONW: 2.77% for the period ending September 30, 2023, down from 25.75% in FY 2023.
– EPS (Basic & Diluted): ₹0.45 for the period ending September 30, 2023, compared to ₹4.09 in FY 2023.
These financial insights underscore the trajectory and performance of Clinitech Laboratory IPO, highlighting the company’s revenue trends, profitability, and strategic growth.
Statement Of Revenue From Operations
Statement of Other Income
Statement of Other Expenses
Statement of Reserves & Surplus
Statement of Equity Share Capital
Statement of Capitalisation
Financial Ratios
5. Clinitech Laboratory IPO FAQs
Clinitech Laboratory IPO Details
The Clinitech Laboratory IPO opens on July 25, 2024.
The IPO closes on July 29, 2024.
The issue price is ₹96.00 per share.
The IPO will be listed on the BSE SME platform.
The face value of each equity share is ₹10.
Clinitech Laboratory IPO Dates
The basis of allotment date is tentatively set for July 30, 2024.
Refunds will be initiated on July 31, 2024.
The shares will be credited to Demat accounts on July 31, 2024.
The tentative listing date is August 1, 2024.
Clinitech Laboratory IPO Issue Details
It is a fixed price issue.
The issue size is ₹5.78 crore.
The entire issue, ₹5.78 crore, is a fresh issue.
The retail quota is 50% of the net issue.
The market lot size is 1200 shares.
The minimum HNI lot is 2400 shares, which amounts to ₹230,400.
Clinitech Laboratory Business Model
Clinitech Laboratory provides diagnostic and healthcare tests through a chain of diagnostic centers.
Clinitech Laboratory operates 8 diagnostic centers in and around Thane and Navi Mumbai.
The key tests include biochemistry, immunology, hematology, molecular biology, serology, microbiology, and histopathology tests.
Clinitech Laboratory is accredited by NABL (National Accreditation Board for Testing and Calibration Laboratories).
The promoters are Jagdish Umakant Nayak and Jyoti Jagdish Nayak, who have over 30 years of experience in the diagnostic business.
Clinitech Laboratory Financial Data
The revenue was ₹643.92 lakhs.
The PAT was ₹37.12 lakhs.
The assets amounted to ₹560.79 lakhs.
The net worth was ₹354.80 lakhs.
The EPS was ₹2.37.
The debt/equity ratio was 0.24.
The EBITDA margin was 15.87%.
The RONW was 10.46%.
The revenue increased by 1.19%.
The PE ratio was 40.51.
For Further Inquiries and Information:
Should you have any additional inquiries or require further information regarding Clinitech Laboratory IPO or the DRHP, we welcome you to reach out to us directly via email at swifttopics365@gmail.com. Our team is dedicated to providing comprehensive assistance and addressing any queries you may have.
Exclusive IPO Allotment Calculator:
Furthermore, we highly recommend making use of India’s exclusive IPO allotment calculator to assess the chances of allotment for the Clinitech Laboratory IPO This tool offers valuable insights into the allotment process, allowing you to plan your investments strategically.
Stay Informed with Our Updates:
We sincerely appreciate your continued interest in Clinitech Laboratory IPO. To stay informed and up-to-date with our latest developments, announcements, and industry insights, keep a close eye on our communications. We are committed to keeping you informed about the exciting progress and milestones in the Clinitech Laboratory IPO journey.
Thank you for choosing Swifttopics.com, and we look forward to assisting you with any information you may require.